 |
|
Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
Sun Kyoung Kang, Hyun Joo Bae, Woo Sun Kwon, Jingmin Che, Tae Soo Kim, Hyun Cheol Chung, Sun Young Rha
Genomics Inform. 2020;18(4):e37 Published online 2020 Dec 22 DOI: https://doi.org/10.5808/GI.2020.18.4.e37
|
|
Citations to this article as recorded by
 GCNT3-mediated glycosylation in cancer biology: Implications for tumorigenesis, metastasis, and therapeutic targeting
Lin Zhong, Bhagyalakshmi Purushothaman, Qiang Tu, Seenivasan Boopathi, Youming Zhang
International Journal of Biological Macromolecules.2025; 315: 144427. CrossRef Wnt signaling in gastric cancer: current progress and future prospects
Ruyue Han, Jing Yang, Yingying Zhu, Runliang Gan
Frontiers in Oncology.2024;[Epub] CrossRef BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernández-Guerrero, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, B
Nature Communications.2023;[Epub] CrossRef Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
Hui-Yan Sun, Song-Tao Du, Ya-Yun Li, Guang-Tong Deng, Fu-Rong Zeng
World Journal of Gastrointestinal Oncology.2022; 14(1): 75. CrossRef Epigenetic signatures in gastric cancer: current knowledge and future perspectives
Fatma Sogutlu, Mert Pekerbas, Cigir Biray Avci
Expert Review of Molecular Diagnostics.2022; 22(12): 1063. CrossRef
|